Alternative splicing of interleukin-33 and type 2 inflammation in asthma
Type 2 inflammation occurs in a large subgroup of asthmatics, and novel cytokine-directed therapies are being developed to treat this population. In mouse models, interleukin-33 (IL-33) activates lung resident innate lymphoid type 2 cells (ILC2s) to initiate airway type 2 inflammation. In human asthma, which is chronic and difficult to model, the role of IL-33 and the target cells responsible for persistent type 2 inflammation remain undefined. Full-length IL-33 is a nuclear protein and may function as an "alarmin" during cell death, a process that is uncommon in chronic stable asthma. We demonstrate a previously unidentified mechanism of IL-33 activity that involves alternative transcript splicing, which may operate in stable asthma. In human airway epithelial cells, alternative splicing of the IL-33 transcript is consistently present, and the deletion of exons 3 and 4 (Δ exon 3,4) confers cytoplasmic localization and facilitates extracellular secretion, while retaining signaling capacity. In nonexacerbating asthmatics, the expression of Δ exon 3,4 is strongly associated with airway type 2 inflammation, whereas full-length IL-33 is not. To further define the extracellular role of IL-33 in stable asthma, we sought to determine the cellular targets of its activity. Comprehensive flow cytometry and RNA sequencing of sputum cells suggest basophils and mast cells, not ILC2s, are the cellular sources of type 2 cytokines in chronic asthma. We conclude that IL-33 isoforms activate basophils and mast cells to drive type 2 inflammation in chronic stable asthma, and novel IL-33 inhibitors will need to block all biologically active isoforms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 113(2016), 31 vom: 02. Aug., Seite 8765-70 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gordon, Erin D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.02.2018 Date Revised 18.03.2022 published: Print-Electronic GENBANK: KX463463, KX463464 Citation Status MEDLINE |
|---|
| doi: |
10.1073/pnas.1601914113 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM262568535 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM262568535 | ||
| 003 | DE-627 | ||
| 005 | 20231224202036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1073/pnas.1601914113 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0875.xml |
| 035 | |a (DE-627)NLM262568535 | ||
| 035 | |a (NLM)27432971 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gordon, Erin D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Alternative splicing of interleukin-33 and type 2 inflammation in asthma |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2018 | ||
| 500 | |a Date Revised 18.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a GENBANK: KX463463, KX463464 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Type 2 inflammation occurs in a large subgroup of asthmatics, and novel cytokine-directed therapies are being developed to treat this population. In mouse models, interleukin-33 (IL-33) activates lung resident innate lymphoid type 2 cells (ILC2s) to initiate airway type 2 inflammation. In human asthma, which is chronic and difficult to model, the role of IL-33 and the target cells responsible for persistent type 2 inflammation remain undefined. Full-length IL-33 is a nuclear protein and may function as an "alarmin" during cell death, a process that is uncommon in chronic stable asthma. We demonstrate a previously unidentified mechanism of IL-33 activity that involves alternative transcript splicing, which may operate in stable asthma. In human airway epithelial cells, alternative splicing of the IL-33 transcript is consistently present, and the deletion of exons 3 and 4 (Δ exon 3,4) confers cytoplasmic localization and facilitates extracellular secretion, while retaining signaling capacity. In nonexacerbating asthmatics, the expression of Δ exon 3,4 is strongly associated with airway type 2 inflammation, whereas full-length IL-33 is not. To further define the extracellular role of IL-33 in stable asthma, we sought to determine the cellular targets of its activity. Comprehensive flow cytometry and RNA sequencing of sputum cells suggest basophils and mast cells, not ILC2s, are the cellular sources of type 2 cytokines in chronic asthma. We conclude that IL-33 isoforms activate basophils and mast cells to drive type 2 inflammation in chronic stable asthma, and novel IL-33 inhibitors will need to block all biologically active isoforms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a alternative splicing | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a basophils | |
| 650 | 4 | |a interleukin-33 | |
| 650 | 4 | |a type 2 inflammation | |
| 650 | 7 | |a IL1RL1 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-1 Receptor-Like 1 Protein |2 NLM | |
| 650 | 7 | |a Interleukin-33 |2 NLM | |
| 700 | 1 | |a Simpson, Laura J |e verfasserin |4 aut | |
| 700 | 1 | |a Rios, Cydney L |e verfasserin |4 aut | |
| 700 | 1 | |a Ringel, Lando |e verfasserin |4 aut | |
| 700 | 1 | |a Lachowicz-Scroggins, Marrah E |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, Michael C |e verfasserin |4 aut | |
| 700 | 1 | |a Wesolowska-Andersen, Agata |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez, Jeanmarie R |e verfasserin |4 aut | |
| 700 | 1 | |a MacLeod, Hannah J |e verfasserin |4 aut | |
| 700 | 1 | |a Christian, Laura S |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Shaopeng |e verfasserin |4 aut | |
| 700 | 1 | |a Barry, Liam |e verfasserin |4 aut | |
| 700 | 1 | |a Woodruff, Prescott G |e verfasserin |4 aut | |
| 700 | 1 | |a Ansel, K Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Nocka, Karl |e verfasserin |4 aut | |
| 700 | 1 | |a Seibold, Max A |e verfasserin |4 aut | |
| 700 | 1 | |a Fahy, John V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 113(2016), 31 vom: 02. Aug., Seite 8765-70 |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:2016 |g number:31 |g day:02 |g month:08 |g pages:8765-70 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1073/pnas.1601914113 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 113 |j 2016 |e 31 |b 02 |c 08 |h 8765-70 | ||